GENZYME CORP
S-8, EX-5, 2000-12-15
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: GENZYME CORP, S-8, 2000-12-15
Next: GENZYME CORP, S-8, EX-23.1, 2000-12-15



<PAGE>


                                                                     EXHIBIT 5

                               Palmer & Dodge LLP
                                One Beacon Street
                           Boston, Massachusetts 02108

TELEPHONE: (617) 573-0100                              FACSIMILE: (617) 227-4420


                                December 14, 2000


Genzyme Corporation
One Kendall Square
Cambridge, Massachusetts 02139

         We are rendering this opinion in connection with the Registration
Statement on Form S-8 (the "Registration Statement") filed by Genzyme
Corporation (the "Company") with the Securities and Exchange Commission (the
"Commission") under the Securities Act of 1933, as amended (the "Act"), on or
about the date hereof. The Registration Statement relates to 1,488,630 shares
of Genzyme General Division common stock, $0.01 par value (the "Shares"),
that are issuable upon the exercise of options assumed by the Company in
connection with the merger of GelTex Pharmaceuticals, Inc. ("GelTex") into a
wholly-owned subsidiary of the Company pursuant to the terms of the Agreement
and Plan of Merger dated as of September 11, 2000, as amended, by and among
the Company, GelTex and Titan Acquisition Corp. These options were originally
granted to employees and directors under GelTex' Amended and Restated 1992
Equity Incentive Plan and its Amended and Restated 1995 Director Stock Option
Plan and are currently exercisable upon the same terms and conditions as
provided in the GelTex plan under which the options were issued, except that
the assumed options are exercisable for the number of shares of Genzyme
General Division common stock equal to the number of shares of GelTex common
stock for which the options were exercisable immediately before the merger
multiplied by 0.7272 (rounded down to the nearest whole share) at a per share
exercise price equal to the exercise price for which the options were
exercisable immediately before the merger divided by 0.7272 (rounded up to
the nearest whole cent) (the "Exercise Terms").

         We have acted as your counsel in connection with the preparation of the
Registration Statement and are familiar with the proceedings taken by the
Company in connection with authorization, issuance and sale of the Shares. We
have examined all such documents as we consider necessary to enable us to render
this opinion.

         Based upon the foregoing, we are of the opinion that when issued in
accordance with the Exercise Terms, the Shares will be duly authorized, validly
issued, fully paid and nonassessable.

         We hereby consent to the filing of this opinion as a part of the
Registration Statement.


                                   Very truly yours,

                                   /s/ Palmer & Dodge LLP

                                   Palmer & Dodge LLP




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission